Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CTXR

CTXR - Citius Pharmaceuticals Inc Stock Price, Fair Value and News

$0.78-0.05 (-6.02%)
Market Closed

80/100

CTXR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

80/100

CTXR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.27

Target 3M

$1

Target 6M

$1.15

CTXR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CTXR Price Action

Last 7 days

-2.5%

Last 30 days

-6.0%

Last 90 days

-50.3%

Trailing 12 Months

-73.2%

CTXR RSI Chart

CTXR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CTXR Valuation

Market Cap

16.2M

Price/Earnings (Trailing)

-0.41

Price/Sales (Trailing)

552.15

EV/EBITDA

-0.31

Price/Free Cashflow

-0.61

CTXR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.27

Target 3M

$1

Target 6M

$1.15

CTXR Fundamentals

CTXR Revenue

Revenue (TTM)

29.3K

CTXR Earnings

Earnings (TTM)

-39.7M

Earnings Growth (Yr)

21.07%

Earnings Growth (Qtr)

5%

CTXR Profitability

EBT Margin

-131885.41%

Return on Equity

-58.83%

Return on Assets

-30.35%

Free Cashflow Yield

-164%

CTXR Investor Care

Shares Dilution (1Y)

168.70%

Diluted EPS (TTM)

-3.43

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
201434.6K29.3K00
201322.1K18.7K29.1K0
201212.6K12.9K15.6K0
20110013.4K7.6K
20100000
Get all data in R, Python etc through our Historical Stock Data APIs

About Citius Pharmaceuticals Inc

CTXR
Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
 CEO
 WEBSITEcitiuspharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES21

Citius Pharmaceuticals Inc Frequently Asked Questions

CTXR is the stock ticker symbol of Citius Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Citius Pharmaceuticals Inc is 16.2 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CTXR's fair value in chart for subscribers.

The fair value guage provides a quick view whether CTXR is over valued or under valued. Whether Citius Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Citius Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CTXR.

As of Wed Jan 28 2026, CTXR's PE ratio (Price to Earnings) is -0.41 and Price to Sales (PS) ratio is 659.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CTXR PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Citius Pharmaceuticals Inc has provided -0.493 (multiply by 100 for percentage) rate of return.